Par Pharma (PRX) Shares Surge Midday as BofA Merrill Upgrades to Buy
Tweet Send to a FriendGet Alerts PRX Hot Sheet
Price: $49.98 --0%
Rating Summary:
2 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 36 | New: 12
Rating Summary:
2 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 36 | New: 12
Trade PRX Now!
Shares of Par Pharmaceutical (NYSE: PRX) have just jumped well into positive territory following an intraday upgrade from BofA Merrill. The stock is now up 3.6 percent to $30.15.
BofA Merrill now rates Par Pharma shares a Buy, up from Neutral previously.
For more ratings news on Par Pharmaceutical click here and for the rating history of Par Pharmaceutical click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
BofA Merrill now rates Par Pharma shares a Buy, up from Neutral previously.
For more ratings news on Par Pharmaceutical click here and for the rating history of Par Pharmaceutical click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Goldman Sachs Upgrades Meritor (MTOR) to Buy
- Iberia Capital Upgrades James River Coal (JRCC) to Outperform
- Deutsche Bank Upgrades priceline.com (PCLN) to Buy
Create E-mail Alert Related Categories
UpgradesRelated Entities
Bank of America
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
